KB-1237

Faricimab

Background

Faricimab is an example of IgG-based antibody with the ability to bind two therapeutic targets, designed based on CrossMab technology. It comprises one Fab with specificity for VEGF and another Fab with specificity for ANG-2, and is in Phase III trials for the treatment of wet-AMD and DME. By blocking two soluble targets, dual-acting antibodies could combine the activities of two pathway-modulating molecules into one for enhanced efficacy.

Specifications

Catalog Number:
KB-1237
Cell Line Name:
Faricimab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
ANG2&VEGF
Species Reactivity:
Human
Application:
ELISA | FACS Blocking
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS Blocking

References

1.Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM: Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells. 2020 Aug 10;9(8). 2.Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288.
Please enable JavaScript in your browser to complete this form.